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 USE OF THE IMS CORE DIABETES MODEL (CDM) IN A LONG-TERM 
PROJECTED HEALTH ECONOMIC COMPARISON OF CSII AND MDI 
TREATMENTS OF TYPE 1 DIABETES (T1D) IN A NEWLY-DIAGNOSED 
POPULATION OF PAEDIATRIC PATIENTS. 
Ridyard CH1, Blair J2, Hughes DA1, on behalf of the SCIPI Trial Investigators .3 
1Bangor University, Bangor, United Kingdom, 2Alder Hey Children's NHS Foundation Trust, Liverpool, United 
Kingdom, 3Clinical Trials Research Centre, Liverpool, United Kingdom 
OBJECTIVES: Continuous subcutaneous insulin infusions (CSII) are an alternative to multiple daily injections 
(MDI) of insulin for glycaemic control and reducing the risks of developing long term microvascular and 
macrovascular complications in type 1 diabetes (T1D). As part of a randomised clinical trial (SCIPI, 
ISRCTN29255275) we aimed to estimate and compare the long term (60 year) cost-effectiveness of CSII 
treatment with MDI in paediatrics newly diagnosed with T1D. METHODS: Patients were randomised equally to 
CSII or MDI and followed-up for 1 year. Glycated haemoglobin levels (HbA1c), measured at randomisation, 3, 6, 
9 and 12 month were used to project future differences between CSII and MDI. Mean total costs for MDI and CSII 
were estimated at £2,666 and £4,533 for year 1, and £1,665 and £3,303 in subsequent years. Quality adjusted 
life years (QALYs) were estimated using CORE default settings. Simulations were run for 1000 patients over a 
thousand iterations and a 60-year timeframe. All costs and outcomes were discounted at 3.5%. RESULTS: Data 
on HbA1c were available for 97% of participants (CSII=143 MDI=142). Simulations were run with: (i) projected 
0.3% HbA1c improvement in CSII patients over 60 years, giving a cost/QALY gain of £207,153 (95% CI: £14,944; 
£399,362); and (ii) projected 0.2% HbA1c improvement in MDI patients over 60 years, resulting in CSII being 
dominated. CONCLUSIONS: Based on these exploratory analyses, CSII does not appear to be cost-effective in 
patients representative of the study population for a projected 60-year lifetime and is dominated by MDI. 
However, the CDM has not been validated in paediatric populations, and no reliable data on comparative costs 
and outcomes are available beyond 12 months. 
 
